-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Under the peak of severe disease, people are most eager for new crown treatment drugs
.
However, in the journey of a large wave of enterprises to follow-up research and development, it seems that no company has taken the lead in breaking through the siege
.
.
At present, there are only 2 small molecule drugs for new coronary pneumonia that have been marketed in China, including Azvudine of real biology and Paxlovid
of Pfizer.
In addition, Merck's Molnupiravir and Japan's Shionogi Pharmaceutical's Xocova are in the marketing process
.
From the price point of view, the price of azvudine of real creatures ranges from 330-350 yuan / box, while Pfizer's Paxlovid is about 2300 yuan / box
.
What's more difficult is that at present, Paxlovid is difficult to find, and the generic version of Paxlovid is being bought and sold
in secret.
in secret.
In this context, the inclusion of Paxlovid in medical insurance negotiations/collective procurement may be able to achieve a win-win situation
of volume for price.
Why Paxlovid?
Why Paxlovid?In the development of new crown oral drugs, 3CL protease inhibitors are the small molecule drugs
with the largest number of varieties under development and the most promising in the industry.
According to incomplete statistics, there are about 44 new crown pneumonia drugs developed based on 3CL protease targets in the world, and only Pfizer's Paxlovid has been approved for marketing
.
.
Paxlovid is Pfizer's original new crown drug, which is a combination of 3CL protease inhibitor PF-07321332 and low-dose ritonavir, which helps slow down the metabolism or breakdown of PF-07321332, so that it can maintain an effective concentration in the body for a long time, with its antiviral activity
.
Clinical trials have shown that Paxlovid can reduce hospitalization or mortality in new crown patients by 89% and 88%, respectively, compared with placebo
Clinical trials have shown that Paxlovid can reduce hospitalization or mortality in new crown patients by 89% and 88%, respectively, compared with placeboExcellent clinical data has enabled Paxlovid to quickly open up markets between countries, and China is no exception
.
In February this year, the State Food and Drug Administration urgently approved the import registration of Paxlovid; In March, the National Health Insurance Administration included Paxlovid in Medicare
.
But soon, Paxlovid's price was criticized by the market
.
.
At present, the use of Paxlovid in the United States is that after the US government purchases (about 300 yuan), patients only need to pay 60 yuan to get the drug
.
At the same time, Pfizer signed a licensing agreement with MPP to allow the production and sale of generic drugs, allowing them to be supplied to 95 low- and middle-income countries in Southeast Asia and Africa at a price of about US$
20.
In China, Paxlovid sells online at a price of 2980 yuan / box, and the price in the hospital is about 2300 yuan / box, a box is a course of treatment, which is a big burden, and only a few regions temporarily include it in medical insurance
.
.
As a result, China is basically one of
the most expensive countries in the world for Paxlovid.
"Just need" under the peak of severe disease
"Just need" under the peak of severe diseaseThe new crown pneumonia has affected our lives for 3 years, and the end of the new crown pandemic is everyone's expectation
.
Coincidentally, this month (December) the domestic epidemic prevention and control policy has undergone major changes, and various places have intensively issued loose policies for epidemic prevention optimization and gradually liberalized epidemic control measures
.
With the liberalization of epidemic prevention policies, the number of infected people across the country has risen
sharply.
Disease control experts pointed out that after the first wave of shock and then back to a plateau, 80% to 90% of people may eventually experience infection
.
.
Although most of the current people are mild diseases, but for the aging process is accelerating, and the population base is huge, the elderly population and people with underlying diseases, the results after infection are still not optimistic, for special groups, the demand for the development and use of new crown specific drugs will increase rapidly
.
How to reduce the burden of patients and medical insurance funds and protect people's health to the greatest extent?
How to reduce the burden of patients and medical insurance funds and protect people's health to the greatest extent?Include relevant effective therapeutic drugs in the medical insurance negotiation and collective procurement catalogue or one of
the solutions.
Unleash the power of "combo punches"
Unleash the power of "combo punches"In the domestic market, the Health Insurance Bureau, as the largest and single payer, led the formation of negotiated prices, which was very favorable for drug price reduction
.
In the direction of centralized procurement, eight centralized procurement has been carried out in China (the sixth batch is insulin special centralized procurement), and the average reduction rate of the selected varieties is basically stable at 50%, which has saved 120 billion yuan
in drug costs for the region/the whole country a year.
The power of the "combination fist" of medical insurance negotiation and collective procurement can be
imagined.
imagined.
To this end, it is proposed to include Paxlovid in it, specifically:
Include Paxlovid in health care negotiations, special affairs, emergency negotiations
.
.
After several years of exploration, medical insurance negotiations have become systematic, and the most direct benefit for patients and medical insurance is that they have a say in the reasonable price of drugs
.
For example, Ascletis danorevir sodium tablets dropped from 238.
07 yuan before negotiations to 8.
3 yuan; Biogen's sky-high drug nocinaxen sodium injection dropped from 700,000 to 33,000.
.
.
Various "soul haggling" in previous rounds of negotiations have repeatedly dominated the screen, directly benefiting patients and effectively reducing medical expenses
.
Therefore, it is recommended to conduct national medical insurance negotiations again, and reduce the price by including it in the national medical insurance, so that enterprises can achieve rapid volume expansion and achieve a win-win effect
when the demand for specific drugs may rise sharply in China.
Paxlovid will be included in the national centralized procurement, and the volume will be exchanged for price to further reduce the price of
drugs.
drugs.
In the process of centralized procurement, although the price of enterprises has faced challenges, and the price of many drugs has fallen off a cliff, enterprises have also obtained the opportunity to exchange price for volume and seize market share
.
If Paxlovid joins the centralized procurement, the state can use the method of centralized procurement negotiations to make concessions to enterprises, significantly reduce drug prices, let enterprises exchange price for quantity, reduce the burden of drug payment, and better protect the health of
the people.
brief summary
brief summaryAccording to reports, this year's national medical insurance on-site negotiations will be held from January 5 to January 8, and the high-profile negotiation stage has entered the "countdown"
.
Will Paxlovid be the first to cut prices in Medicare negotiations? The most exciting part is coming soon and is worth looking forward to
.
.
